Atorvastatin intra-subject Variability [Study As­sess­ment]

posted by nobody – 2017-09-27 10:11  – Posting: # 17832
Views: 3,351

» Chance?
 Maybe, but...

» Better assay?
 No

» Design differences?
 How?

» Lesser within-batch variability (-ies) than in the studies you compare to?
 Variability has been attributed to various physiological sources, including e.g. liver function, transporter status:

https://www.ncbi.nlm.nih.gov/pubmed/22167570
https://www.ncbi.nlm.nih.gov/pubmed/21548957
https://www.ncbi.nlm.nih.gov/pubmed/20818835
—
Kindest regards, nobody

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,871 posts in 4,212 threads, 1,364 registered users;
online 13 (0 registered, 13 guests [including 9 identified bots]).
Forum time (Europe/Vienna): 13:43 CEST

A drug is not bad. A drug is a chemical compound.
The problem comes in when people who take drugs treat them
like a license to behave like an asshole.    Frank Zappa

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5